このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

CohBar 過去の業績

過去基準チェック /06

CohBarの収益は年平均-4%で減少しているが、Biotechs業界はgrowingで15.9%年平均の収益となった。

主要情報

-4.0%

収益成長率

5.5%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-133.5%
ネット・マージン	n/a
前回の決算情報	30 Jun 2023

Recent updates

収支内訳

CohBar の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:CWBR 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Jun 23	-13	9	4
31 Mar 23	-11	6	5
31 Dec 22	-12	6	6
30 Sep 22	-11	7	5
30 Jun 22	-12	7	5
31 Mar 22	-15	8	7
31 Dec 21	-15	8	8
30 Sep 21	-17	7	10
30 Jun 21	-17	7	9
31 Mar 21	-16	6	8
31 Dec 20	-16	6	7
30 Sep 20	-15	6	6
30 Jun 20	-15	6	7
31 Mar 20	-14	6	7
31 Dec 19	-13	6	7
30 Sep 19	-14	6	7
30 Jun 19	-15	6	8
31 Mar 19	-15	6	9
31 Dec 18	-16	5	10
30 Sep 18	-14	4	10
30 Jun 18	-13	4	9
31 Mar 18	-11	3	8
31 Dec 17	-10	3	7
30 Sep 17	-9	3	6
30 Jun 17	-7	3	5
31 Mar 17	-7	3	4
31 Dec 16	-6	2	4
30 Sep 16	-6	2	3
30 Jun 16	-5	2	3
31 Mar 16	-4	2	2
31 Dec 15	-4	2	2
30 Sep 15	-3	2	1
30 Jun 15	-3	1	1
31 Mar 15	-2	2	1
31 Dec 14	-2	1	1
30 Sep 14	-2	1	0
30 Jun 14	-1	1	0
31 Mar 14	-1	0	0

質の高い収益: CWBRは現在利益が出ていません。

利益率の向上: CWBRは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CWBRの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。

成長の加速: CWBRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CWBRは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: CWBRは現在利益が出ていないため、自己資本利益率 ( -133.49% ) はマイナスです。

CohBar 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

CohBar, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CohBar, Inc. to Report Q2, 2022 Results on Aug 15, 2022

CohBar, Inc. to Report Q1, 2022 Results on May 16, 2022

CohBar, Inc. to Report Q3, 2020 Results on Nov 16, 2020

CohBar, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Recent updates

CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index

CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index

CohBar Expects the Trading in its Common Stock to be Suspended Upon the Opening of Business on November 29, 2023 and Nasdaq to File Form 25-NSE with the SEC to Formally Delist CohBar's Common Stock

Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. (NasdaqCM:CWBR) in a reverse merger transaction.

New major risk - Share price stability

Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. (NasdaqCM:CWBR) for approximately $130 million in a reverse merger transaction.

High number of new and inexperienced directors

CohBar, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CohBar stock gains on 1-for-30 reverse stock split

CohBar, Inc. to Report Q2, 2022 Results on Aug 15, 2022

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation

CohBar Announces Extension of Nasdaq Compliance Period

CohBar, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$2.17

High number of new and inexperienced directors

CohBar, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target decreased to US$5.63

Independent Director recently bought US$96k worth of stock

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

High number of new directors

CohBar, Inc. Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar, Inc.(NasdaqCM:CWBR) dropped from Russell 3000E Index

CEO & Director Steven Engle has left the company

Price target decreased to US$6.10

CohBar appoints Joseph Sarret as CEO and Director

CohBar, Inc. Announces the Selection of CB5138-3

New 90-day high: US$1.65

CohBar, Inc. Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS

CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS

New 90-day high: US$1.54

CohBar, Inc. Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome Model

New 90-day high: US$1.21

CohBar EPS in-line

CohBar, Inc. to Report Q3, 2020 Results on Nov 16, 2020

CohBar (CWBR) Investor Presentation - Slideshow

CohBar, Inc. Announces New Preclinical Data Demonstrating That Combination of A Cb5138 Analog with nintedanib

CohBar, Inc. has completed a Composite Units Offering in the amount of $15.006 million.

New 90-day low - US$1.36

CohBar, Inc. to Report Q2, 2020 Results on Aug 13, 2020

New 90-day low - US$1.46

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06